NSAIDs such as mefenamic acid are medications that relieve pain, minimize inflammation and lower fever by preventing the production of prostaglandins which are, chemical messengers that contribute to inflammation and pain. This research focuses on mefenamic acid hydrazide synthesis for Alzheimer disease. The symptoms of Alzheimer's disease include the breakdown of acetylcholine-producing neurons and a decrease in acetylcholine levels in the brain, which is attributed to the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), It mainly affects cognitive function, memory, and behavior. NSAIDs have been shown to inhibit the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), which are enzymes that break down acetylcholine in the brain. AChE and BuChE inhibition can lead to increased levels of acetylcholine. The mefenamic acid hydrazide derivative is synthesized in two steps, the reaction of mefenamic acid with thionyl chloride in toluene under reflux at temperature of 60 to 70 °C for 15 to 20 hour is a first step of the reaction. After confirming our mefenamic acid chloride synthesis with the help of repeated TLC, mefenamic acid chloride is treated with benzoyl hydrazine under reflux to get hydrazide derivative of mefenamic acid. The synthesis of final hydrazide derivative of mefenamic acid is confirmed by the characterization techniques which include Fourier transform infrared spectroscopy and UV-Visible spectrophotometer.

Index Terms- Synthesis, Characterization, Mefenamic Acid Hydrazide Derivative, Drug Development, Pharmaceutical Chemistry